Fidelity SPDR Advertisement
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

RXII RSS Feed
Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator now invest, zoriden, Inoviorulez, pistol1p
Search This Board:
Last Post: 11/17/2014 11:13:38 PM - Followers: 78 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.



RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.




This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
 

Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%
 



http://www.rxipharma.com/

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RXII
Current Price
Volume:
Bid Ask Day's Range
Wiki
RXII News: RXi Pharmaceuticals to Present New Data in its First Phase 2a Clinical Trial with RXI-109 10/07/2014 07:02:00 AM
RXII News: RXi Pharmaceuticals Presented an Update on the Company's Dermatology and Ophthalmology Franchises 09/11/2014 07:02:00 AM
RXII News: RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference 09/03/2014 07:02:00 AM
RXII News: RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014 08/14/2014 07:05:00 AM
RXII News: RXi Pharmaceuticals Celebrates Expansion of its Operations in Massachusetts 07/02/2014 07:02:00 AM
PostSubject
#1558  Sticky Note My Seeking Alpha article interview with the CEO Inoviorulez 09/23/14 09:54:38 AM
#1546  Sticky Note New Seeking Alpha article. http://m.seekingalpha.com/article/2502925-after-a-40- Titan V 09/17/14 08:26:56 PM
#1605   Seeking alpha: Update: RXi Pharmaceuticals Reports Q3 Earnings; My tomsylver 11/17/14 11:13:38 PM
#1604   RXi Pharmaceuticals Reports Financial Results for the Third tomsylver 11/13/14 02:46:03 PM
#1603   website and financial statement press release..... 123tom 11/13/14 02:14:34 PM
#1602   The technical chart pattern now.... 123tom 11/12/14 05:47:59 PM
#1601   Low volume for most of the last couple pistol1p 11/04/14 12:23:38 AM
#1600   Its truly a bummer for you so far. JDLAXXE 11/04/14 12:21:15 AM
#1599   Hey, I've held this from $5.50 of 1k 1 million 11/03/14 05:55:03 PM
#1598   lol.....looks like the street wasn't impressed at all.... Myth 11/03/14 10:13:47 AM
#1597   Should be. Was above 3 before the 1 Titan V 11/02/14 11:32:22 PM
#1596   I think it'll be 3-4 by January JDLAXXE 11/02/14 11:27:22 PM
#1595   This patent news appears to be from March Titan V 10/26/14 08:17:59 PM
#1594   Patent news...Moving forward now invest 10/24/14 01:23:44 PM
#1593   Holding LT as well. Only going to sell Titan V 10/21/14 11:21:21 PM
#1592   2%+ today on light volume. pistol1p 10/21/14 10:49:59 PM
#1591   So we get a 10% pop today and pistol1p 10/20/14 11:25:19 PM
#1590   I appreciate the update and your thoughts. pistol1p 10/19/14 07:45:42 PM
#1589   Now it will probably go up steadily, but Inoviorulez 10/18/14 12:31:09 PM
#1588   Long way to go yet, but 4-5% per pistol1p 10/17/14 09:32:14 PM
#1587   Closed at the HOD: $1.80. pistol1p 10/16/14 09:26:25 PM
#1586   I have a bulk of my shares pre zoriden 10/16/14 05:18:26 PM
#1585   RXII chart picture is visible for target zones.... 123tom 10/16/14 04:37:42 PM
#1584   It is always slow in the form of zoriden 10/16/14 04:20:47 PM
#1583   Dow down 400 points. Low volume compared to Titan V 10/15/14 02:12:13 PM
#1582   where is everybody........ 123tom 10/15/14 01:57:19 PM
#1581   I bought some more today...... 123tom 10/13/14 02:56:36 PM
#1580   It's definitely at a great buying price, no Black sunshine 10/09/14 08:16:47 PM
#1579   ...shall we buy more RXII then...? 123tom 10/09/14 07:59:20 PM
#1578   Whole market was terrible. Kind of disappointing Black sunshine 10/09/14 07:56:26 PM
#1577   Guys, what Happened today ??? 123tom 10/09/14 06:30:39 PM
#1576   BACK 2 NOWHERE LAND!!!!!!!! THE INSIDE WORLD OF 1 million 10/09/14 01:42:05 PM
#1575   Seeking alpha Update: RXi Pharmaceuticals Presents New RXI-109 tomsylver 10/08/14 09:38:43 AM
#1574   Looks like things calming down and moving in zoriden 10/08/14 07:14:39 AM
#1573   Stock closed right on the 20dma (mid-Bollinger Band), value1008 10/07/14 04:06:42 PM
#1572   Good article about Rxi Pharmaceuticals (RXII) BiotehPickList 10/07/14 02:51:29 PM
#1571   Nice to get some slight tailwinds, too, in value1008 10/07/14 12:27:50 PM
#1570   Great news! I posted it and a comment value1008 10/07/14 12:12:14 PM
#1569   RXi Pharmaceuticals to Present New Data in its Inoviorulez 10/07/14 08:05:20 AM
#1568   Well, that's not the s/p movement I was value1008 10/01/14 01:06:46 PM
#1567   Some institutions may have been selling this into value1008 10/01/14 09:51:39 AM
#1566   Traders that have 0 knowledge hurt this but zoriden 10/01/14 09:25:41 AM
#1565   Yep tell that to all the traders lol. Inoviorulez 09/30/14 09:27:06 PM
#1564   http://finance.yahoo.com/news/rxi-pharmaceuticals-present-13th-annual-110200856. tomsylver 09/30/14 12:30:55 PM
#1563   I agree with Geert, now is a excellent pistol1p 09/26/14 12:57:12 AM
#1562   Stickied....Lets get this thing going zoriden 09/24/14 03:42:56 PM
#1561   Excellent interview! Thanks for the effort. Mods, can we Titan V 09/23/14 10:24:42 PM
#1560   Probably IND filing for PVR in 2 months Inoviorulez 09/23/14 01:24:39 PM
#1559   Inovio, what do you see as a catalyst value1008 09/23/14 12:00:13 PM
#1558   My Seeking Alpha article interview with the CEO Inoviorulez 09/23/14 09:54:38 AM
#1557   If you are invested for the long term Titan V 09/19/14 09:58:28 PM
#1556   Buy for the loooooong term. dawson-m 09/19/14 01:47:21 PM
PostSubject